ClinicalTrials.gov record
Recruiting Phase 2 Interventional

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

ClinicalTrials.gov ID: NCT07226856

Public ClinicalTrials.gov record NCT07226856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

Study identification

NCT ID
NCT07226856
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Mayo Clinic
Other
Enrollment
43 participants

Conditions and interventions

Interventions

  • Biopsy Procedure Procedure
  • Biospecimen Collection Procedure
  • Computed Tomography Procedure
  • Gemcitabine Drug
  • Imzokitug Biological
  • Magnetic Resonance Imaging Procedure
  • Nab-paclitaxel Drug
  • Nivolumab Biological

Procedure · Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 11, 2025
Primary completion
Nov 30, 2028
Completion
Nov 30, 2028
Last update posted
Dec 21, 2025

2025 – 2028

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Mayo Clinic in Arizona Scottsdale Arizona 85259 Recruiting
Mayo Clinic in Florida Jacksonville Florida 32224-9980 Recruiting
Mayo Clinic in Rochester Rochester Minnesota 55905 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07226856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 21, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07226856 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →